IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant
This study has been completed.
Sponsor:
Vanderbilt University
Information provided by:
Vanderbilt University
ClinicalTrials.gov Identifier:
NCT00179049
First received: September 13, 2005
Last updated: December 12, 2008
Last verified: December 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The investigators' hypothesis is that the graft-versus-tumor effect can be enhanced while minimizing the complications of graft-versus-host disease.
| Condition |
|---|
| Hematopoietic Stem Cell Transplantation Graft vs Host Disease |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant (HSCT) |
Resource links provided by NLM:
Further study details as provided by Vanderbilt University:
| Estimated Enrollment: | 100 |
| Study Start Date: | April 2003 |
| Study Completion Date: | April 2008 |
The investigators' hypothesis is that the graft-versus-tumor effect can be enhanced while minimizing the complications of graft-versus-host disease (GVHD) by determining the qualitative and quantitative changes in T regulatory cells throughout the transplant process. Their understanding of this can lead to new treatment strategies and improved clinical therapeutic implications.
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Patients 18-70 years old undergoing either autologous transplant or allogeneic transplant for various hematologic conditions
Criteria
Inclusion Criteria:
- Patients 18-70 years old undergoing either autologous transplant or allogeneic transplant for various hematologic conditions
Exclusion Criteria:
- Patients < 18 or > 70 years old undergoing either autologous transplant or allogeneic transplant
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00179049
Please refer to this study by its ClinicalTrials.gov identifier: NCT00179049
Locations
| United States, Tennessee | |
| Vanderbilt University Medical Center | |
| Nashville, Tennessee, United States, 37232-5505 | |
Sponsors and Collaborators
Vanderbilt University
Investigators
| Principal Investigator: | Adetola A Kassim, M.D. | Vanderbilt University |
More Information
| Responsible Party: | Adetola A. Kassim, MD, Vanderbilt University |
| ClinicalTrials.gov Identifier: | NCT00179049 History of Changes |
| Other Study ID Numbers: |
BMT 030261 |
| Study First Received: | September 13, 2005 |
| Last Updated: | December 12, 2008 |
Keywords provided by Vanderbilt University:
|
T-Lymphocyte Subsets |
Additional relevant MeSH terms:
|
Graft vs Host Disease Immune System Diseases |
ClinicalTrials.gov processed this record on September 18, 2017